Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimitespib in combination with imatinib in advanced GIST
NCT05245968Phase 1Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of pimitespib in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity at 4 weeks, Maximum tolerable dose at 4 weeks and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
pimitespib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05245968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245968.